Feldan Therapeutics
- 14/06/2023
- Series B
- $16,500,000
Feldan is a biopharmaceutical company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan designed a proprietary, peptide-based technology that enables safe and efficient delivery of various compounds inside cells. The Shuttle technology unlocks the development of a new generation of therapies by giving access to intracellular components beyond the reach of existing drugs. Feldan's pipeline focuses on diseases affecting skin and lungs.
Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the development of the Feldan Shuttle, this approach is starting to show its promises.
- Industry Biotechnology Research
- Website https://www.feldan.com/
- LinkedIn https://www.linkedin.com/company/feldantherapeutics/